BACKGROUND AND PURPOSE: To refine the definition of the malignant magnetic resonance imaging profile in acute stroke patients using baseline diffusion-weighted magnetic resonance imaging (DWI) and perfusion-weighted magnetic resonance imaging (PWI) findings from the pooled DEFUSE/EPITHET database. METHODS: Patients presenting with acute stroke within 3 to 6 hours from symptom onset were treated with tissue plasminogen activator or placebo. Baseline and follow-up DWI and PWI images from both studies were reprocessed using the same software program. A receiver operating characteristic curve analysis was used to identify Tmax and DWI volumes that optimally predicted poor outcomes (modified Rankin Scale 5-6) at 90 days in patients who achieved reperfusion. RESULTS: Sixty-five patients achieved reperfusion and 46 did not reperfuse. Receiver operating characteristic analysis identified a PWI (Tmax>8 s) volume of >85 mL as the optimal definition of the malignant profile. Eighty-nine percent of malignant profile patients had poor outcome with reperfusion versus 39% of patients without reperfusion (P=0.02). Parenchymal hematomas occurred more frequently in malignant profile patients who experienced reperfusion versus no reperfusion (67% versus 11%, P<0.01). DWI analysis identified a volume of 80 mL as the best DWI threshold, but this definition was less sensitive than were PWI-based definitions. CONCLUSIONS: Stroke patients likely to suffer parenchymal hemorrhages and poor outcomes following reperfusion can be identified from baseline magnetic resonance imaging findings. The current analysis demonstrates that a PWI threshold (Tmax>8 s) of approximately 100 mL is appropriate for identifying these patients. Exclusion of malignant profile patients from reperfusion therapies may substantially improve the efficacy and safety of reperfusion therapies. Clinical Trial Registration Information- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00238537.
BACKGROUND AND PURPOSE: To refine the definition of the malignant magnetic resonance imaging profile in acute strokepatients using baseline diffusion-weighted magnetic resonance imaging (DWI) and perfusion-weighted magnetic resonance imaging (PWI) findings from the pooled DEFUSE/EPITHET database. METHODS:Patients presenting with acute stroke within 3 to 6 hours from symptom onset were treated with tissue plasminogen activator or placebo. Baseline and follow-up DWI and PWI images from both studies were reprocessed using the same software program. A receiver operating characteristic curve analysis was used to identify Tmax and DWI volumes that optimally predicted poor outcomes (modified Rankin Scale 5-6) at 90 days in patients who achieved reperfusion. RESULTS: Sixty-five patients achieved reperfusion and 46 did not reperfuse. Receiver operating characteristic analysis identified a PWI (Tmax>8 s) volume of >85 mL as the optimal definition of the malignant profile. Eighty-nine percent of malignant profile patients had poor outcome with reperfusion versus 39% of patients without reperfusion (P=0.02). Parenchymal hematomas occurred more frequently in malignant profile patients who experienced reperfusion versus no reperfusion (67% versus 11%, P<0.01). DWI analysis identified a volume of 80 mL as the best DWI threshold, but this definition was less sensitive than were PWI-based definitions. CONCLUSIONS:Strokepatients likely to suffer parenchymal hemorrhages and poor outcomes following reperfusion can be identified from baseline magnetic resonance imaging findings. The current analysis demonstrates that a PWI threshold (Tmax>8 s) of approximately 100 mL is appropriate for identifying these patients. Exclusion of malignant profile patients from reperfusion therapies may substantially improve the efficacy and safety of reperfusion therapies. Clinical Trial Registration Information- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00238537.
Authors: Jong Hun Kim; Oh Young Bang; David S Liebeskind; Bruce Ovbiagele; Gyeong-Moon Kim; Chin Sang Chung; Kwang Ho Lee; Jeffrey L Saver Journal: Stroke Date: 2010-01-14 Impact factor: 7.914
Authors: Gregory W Albers; Vincent N Thijs; Lawrence Wechsler; Stephanie Kemp; Gottfried Schlaug; Elaine Skalabrin; Roland Bammer; Wataru Kakuda; Maarten G Lansberg; Ashfaq Shuaib; William Coplin; Scott Hamilton; Michael Moseley; Michael P Marks Journal: Ann Neurol Date: 2006-11 Impact factor: 10.422
Authors: Bruce C V Campbell; Søren Christensen; Kenneth S Butcher; Ian Gordon; Mark W Parsons; Patricia M Desmond; P Alan Barber; Christopher R Levi; Christopher F Bladin; Deidre A De Silva; Geoffrey A Donnan; Stephen M Davis Journal: Stroke Date: 2009-12-03 Impact factor: 7.914
Authors: Stephen M Davis; Geoffrey A Donnan; Mark W Parsons; Christopher Levi; Kenneth S Butcher; Andre Peeters; P Alan Barber; Christopher Bladin; Deidre A De Silva; Graham Byrnes; Jonathan B Chalk; John N Fink; Thomas E Kimber; David Schultz; Peter J Hand; Judith Frayne; Graeme Hankey; Keith Muir; Richard Gerraty; Brian M Tress; Patricia M Desmond Journal: Lancet Neurol Date: 2008-02-28 Impact factor: 44.182
Authors: Albert J Yoo; Luis A Verduzco; Pamela W Schaefer; Joshua A Hirsch; James D Rabinov; R Gilberto González Journal: Stroke Date: 2009-04-09 Impact factor: 7.914
Authors: Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton Journal: Lancet Date: 2004-03-06 Impact factor: 79.321
Authors: R von Kummer; U Meyding-Lamadé; M Forsting; L Rosin; K Rieke; W Hacke; K Sartor Journal: AJNR Am J Neuroradiol Date: 1994-01 Impact factor: 3.825
Authors: W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne Journal: JAMA Date: 1995-10-04 Impact factor: 56.272
Authors: Bruce C V Campbell; Archana Purushotham; Soren Christensen; Patricia M Desmond; Yoshinari Nagakane; Mark W Parsons; Maarten G Lansberg; Michael Mlynash; Matus Straka; Deidre A De Silva; Jean-Marc Olivot; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis Journal: J Cereb Blood Flow Metab Date: 2011-07-20 Impact factor: 6.200
Authors: Maarten G Lansberg; Matus Straka; Stephanie Kemp; Michael Mlynash; Lawrence R Wechsler; Tudor G Jovin; Michael J Wilder; Helmi L Lutsep; Todd J Czartoski; Richard A Bernstein; Cherylee W J Chang; Steven Warach; Franz Fazekas; Manabu Inoue; Aaryani Tipirneni; Scott A Hamilton; Greg Zaharchuk; Michael P Marks; Roland Bammer; Gregory W Albers Journal: Lancet Neurol Date: 2012-09-04 Impact factor: 44.182
Authors: Jens Fiehler; Michael Söderman; Francis Turjman; Philip M White; Søren Jacob Bakke; Salvatore Mangiafico; Rüdiger von Kummer; Mario Muto; Christophe Cognard; Jan Gralla Journal: Neuroradiology Date: 2012-09-05 Impact factor: 2.804
Authors: Bruce C V Campbell; Søren Christensen; Mark W Parsons; Leonid Churilov; Patricia M Desmond; P Alan Barber; Kenneth S Butcher; Christopher R Levi; Deidre A De Silva; Maarten G Lansberg; Michael Mlynash; Jean-Marc Olivot; Matus Straka; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis Journal: Ann Neurol Date: 2013-02-26 Impact factor: 10.422
Authors: Kevin N Sheth; John B Terry; Raul G Nogueira; Anat Horev; Thanh N Nguyen; Albert K Fong; Dheeraj Gandhi; Shyam Prabhakaran; Dolora Wisco; Brenda A Glenn; Ashis H Tayal; Bryan Ludwig; Muhammad Shazam Hussain; Tudor G Jovin; Paul F Clemmons; Carolyn Cronin; David S Liebeskind; Melissa Tian; Rishi Gupta Journal: J Neurointerv Surg Date: 2012-10-16 Impact factor: 5.836